The estimated Net Worth of Victor Sandor is at least $7.56 Million dollars as of 17 June 2024. Victor Sandor owns over 6,995 units of Merus N.V stock worth over $4,066,948 and over the last 10 years he sold MRUS stock worth over $3,490,823. In addition, he makes $0 as Non-Executive Independent Director at Merus N.V.
Victor has made over 20 trades of the Merus N.V stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 6,995 units of MRUS stock worth $20,216 on 17 June 2024.
The largest trade he's ever made was exercising 182,191 units of Merus N.V stock on 9 March 2018 worth over $664,997. On average, Victor trades about 24,536 units every 83 days since 2015. As of 17 June 2024 he still owns at least 80,886 units of Merus N.V stock.
You can see the complete history of Victor Sandor stock trades at the bottom of the page.
Dr. Victor Sandor M.D. serves as Non-Executive Independent Director of the Company. From September 2014 to December 2019, Dr. Sandor was the Chief Medical Officer at Array BioPharma (“Array”), a pharmaceutical company, where he oversaw clinical development through regulatory approval of Braftovi and Mektovi for the treatment of BRAFV600E/K mutant melanoma. Prior to joining Array, from September 2014 to June 2019, he was Senior Vice President for Global Clinical Development at Incyte Corporation (“Incyte”), a pharmaceutical company, where he oversaw clinical development through regulatory approval of Jakafi for the treatment of myelofibrosis and polycythemia vera. From February 2010 to September 2014, Dr. Sandor was Vice President and Chief Medical Officer for oncology at Biogen Idec and, from October 2009 to February 2010, held positions of increasing responsibility in oncology product development at AstraZeneca, where he played a lead role in the registration of Arimidex(r) (anastrozole) for adjuvant use and the development of early stage programs through proof-of-concept. Dr. Sandor received his M.D.C.M. from McGill University in Montreal, Canada, and completed his Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland. Sandor is qualified to serve on our board of directors due to his experience in the field of medicine, clinical drug development and scientific experience.
Victor Sandor is 53, he's been the Non-Executive Independent Director of Merus N.V since 2019. There are 10 older and 4 younger executives at Merus N.V. The oldest executive at Merus N.V is Gregory Perry, 59, who is the Independent Non-Executive Vice Chairman of the Board.
Victor's mailing address filed with the SEC is C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472.
Over the last 5 years, insiders at Merus N.V have traded over $76,701,272 worth of Merus N.V stock and bought 4,110,523 units worth $71,063,751 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Corp Incyte. On average, Merus N.V executives and independent directors trade stock every 18 days with the average trade being worth of $4,323,728. The most recent stock trade was executed by Harry Shuman on 20 August 2024, trading 5,000 units of MRUS stock currently worth $251,400.
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Merus N.V executives and other stock owners filed with the SEC include: